Misotac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Misotac

Quick Facts

Property Description
Active ingredient Misoprostol
Form Tablet (Single-ingredient solid dosage form)
Pharmacological class Prostaglandin analogue (Uterotonic, Gastric mucosal protective agent)
Origin Synthetic
WHO Status Essential Medicine

What Type of Medicine is Misotac? (Identity and Classification)

Misotac is a prescription-only medication whose active ingredient is Misoprostol, a compound classified as a prostaglandin analogue. This designation indicates that the drug is a synthetic substance, chemically engineered to mimic the functions of the naturally occurring prostaglandin E1 (PGE1), a critical chemical messenger in the body.

As a prostaglandin analogue, Misoprostol has two primary functional roles: it is recognized as a gastric mucosal protective agent and a uterotonic agent. This unique, dual-action profile distinguishes the substance from many other agents that target only one physiological system.

Misotac's Composition and General Purpose (Form and Benefit)

Misotac is supplied as a tablet, an orally or regionally administered single-ingredient solid dosage form that delivers a precise amount of Misoprostol. Its general purpose is to either protect the digestive lining from potential damage or to stimulate contractions within the uterus.

The tablet preparation ensures the stable delivery of the active ingredient, which works by binding to specific prostaglandin receptors. Misoprostol can modify the uterus to induce contractions. Clinically recognized for its ability to regulate smooth muscle and mucosal defense, Misoprostol is highly valued for its potency across these two distinct physiological systems.

Regulatory References

  1. WHO Essential Medicines List (Misoprostol)
  2. WHO Essential Medicines List

What side effects are possible with Misotac?

Possible Side Effects and Safety Information

The safety profile of Misoprostol (Misotac) is formally classified by government regulatory agencies (e.g., FDA, EMA) based on the frequency and the organ system affected.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped according to how often they were reported in clinical studies, providing a regulatory context for risk assessment. Very Common (ge 1/10) effects include diarrhea and abdominal pain, which often develop early in the course of treatment. Common effects (ge 1/100 to <1/10) include headache, dizziness, flatulence, and uterine hemorrhage (bleeding). Less frequently, Uncommon effects (ge 1/1,000 to <1/100) such as fever and rigors (shivering) are documented, while Rare effects (ge 1/10,000 to <1/1,000) may include uterine rupture in specific obstetric settings.


Serious Adverse Reactions and Safety Constraints

Official labels highlight specific, clinically significant reactions due to their potential severity. Documented serious adverse reactions include severe uterine hemorrhage, amniotic fluid embolism, and uterine rupture, particularly in the presence of risk factors like prior uterine surgery. Furthermore, Misoprostol is subject to a major safety restriction: it is contraindicated for use in pregnant individuals for the purpose of NSAID-induced ulcer prevention, due to the established risks of fetal death, fetal malformation, and premature birth. Safety considerations for special populations, such as older adults and those with renal impairment, are noted in official prescribing information, often suggesting cautious use.

Overdose and Emergency Response

Overdose Manifestations Documented in Regulatory Sources

The official overdose profile for Misoprostol (Misotac) is defined by a range of symptoms and physiological findings documented in government prescribing information. Signs of overexposure include effects on both the central nervous system and the cardiovascular system. Documented clinical manifestations may include sedation, tremor, convulsions, and dyspnea (difficulty breathing). Cardiovascular effects noted in regulatory labels are hypotension (low blood pressure), bradycardia (slow heart rate), and palpitations.

Severe Outcomes and Mandated Emergency Action

Regulatory sources describe the potential for severe, life-threatening outcomes, including uterine rupture (rarely reported) and severe systemic infection such as sepsis. These risks underscore the need for immediate, mandated action. Immediate medical attention must be sought if signs of serious complications occur, such as when the individual has collapsed, experienced a seizure, or is exhibiting prolonged heavy vaginal bleeding (defined as soaking two thick, full-size sanitary pads per hour for two consecutive hours). Urgent medical or surgical intervention may be required to prevent the development of hypovolemic shock.

Official Management Protocol

The management approach for overdosage is defined in official documents as symptomatic and supportive therapy. Regulatory information explicitly states that no specific antidote is known for Misoprostol overdosage.

Therapeutic Uses of Misotac

Quick Facts: Misotac Main Uses

  • Gastrointestinal: May help to reduce the potential for gastric ulcers in individuals taking nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Obstetrics/Gynecology: Used in combination with mifepristone for the medical termination of intrauterine pregnancy through 70 days of gestation.
  • Other Potential Uses: May be used in clinical settings for medical management of early pregnancy loss, cervical preparation, and to help manage postpartum hemorrhage.

Misotac (misoprostol) is a medication utilized in two principal therapeutic domains, as well as for several uses in the obstetrics and gynecology specialties. In the gastrointestinal context, the primary indication is to help reduce the potential for stomach ulcers that can be associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), which include certain pain relievers and arthritis treatments.

The medication is also indicated, in a regulated regimen with mifepristone, for the medical termination of intrauterine pregnancy through 70 days of gestation. This dual-agent regimen is an established therapeutic choice for this specific use. Additionally, misoprostol may be used in certain clinical settings to aid the process of cervical preparation prior to medical procedures and in the management of early pregnancy loss. It may also be administered to help manage heavy bleeding associated with postpartum hemorrhage (PPH) in the immediate period following childbirth.

Eligibility and Restrictions for Use

Misotac (misoprostol) eligibility is strictly defined by regulatory authorities based on population status and pre-existing health conditions. Use must align only with official, label-based criteria.

Contraindications and Absolute Exclusions

Use is absolutely contraindicated in specific populations. The most critical exclusion is pregnancy when the medicine is used for the reduction of NSAID-induced ulcers, due to the risk of abortion and birth defects. Misoprostol is also strictly prohibited for individuals with a known hypersensitivity to the drug or other prostaglandins. When used in a termination regimen, it is contraindicated in cases of confirmed or suspected ectopic pregnancy or certain hemorrhagic disorders.

Population Restriction Regulatory Status
Pregnant Women (for ulcer use) Contraindicated (Boxed Warning)
Hypersensitivity/Allergy Contraindicated
Pediatric Patients (<18) Safety Not Established

Conditional Use and Restrictions

Eligibility is conditional for certain groups. Women of childbearing potential who take Misotac for ulcer prevention must have a negative pregnancy test and commit to using effective contraception throughout therapy. Use requires caution in patients with renal impairment due to altered drug clearance, and in those with a history of prior uterine surgery (such as Cesarean section) due to the risk of uterine rupture. Misoprostol is not recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Misotac (misoprostol) interaction patterns are documented by regulatory authorities, focusing primarily on pharmacodynamic effects and absorption kinetics, rather than metabolic enzyme interactions. Misoprostol's metabolism does not involve the cytochrome P450 (CYP450) enzyme system, so it is not expected to alter the clearance of drugs metabolized by this route.

Documented Interaction Patterns

Type of Interaction Interacting Substance/Class Official Documented Outcome
Pharmacodynamic Other Uterotonic Agents (e.g., Oxytocin) Additive uterine stimulation, increasing the potential for uterine hyperstimulation.
Pharmacokinetic Food Decreased maximum plasma concentration ( C max) and delayed time to peak concentration ( T max); overall absorption (AUC) remains unchanged.
Physiological Antacids (containing Magnesium) Increased potential for diarrhea, an additive effect on the gastrointestinal tract.

Population-Dependent Exposure

For individuals with chronic renal impairment, official prescribing information notes that exposure to the active metabolite, misoprostol acid, is increased. This higher exposure is evidenced by a greater area under the curve (AUC) and a prolonged elimination half-life.

Official regulatory labels do not list any medicinal products or substances as strictly contraindicated for co-administration due to interaction risk, nor do they specify mandatory timing separation rules for co-administration.

Mechanism of Action

Misotac, containing misoprostol, functions as a synthetic prostaglandin E1 (PGE1) analog. Its primary biological targets are prostaglandin E (EP) receptors, specifically acting as a full agonist at the EP2, EP3, and EP4 receptor subtypes located on various cell membranes, notably myometrial cells and gastrointestinal mucosa cells.

Molecular and Intracellular Pathways

The activation of EP3 receptors, which are coupled to the Gi protein, triggers a downstream cascade that inhibits adenylyl cyclase. This inhibition reduces the intracellular concentration of cyclic adenosine monophosphate (cAMP). Conversely, activation of the EP2 and EP4 receptors, coupled to Gs protein, stimulates adenylyl cyclase, leading to an increase in intracellular cAMP levels. The EP3 mediated decrease in cAMP is the dominant signaling pathway in myometrial cells.

System-Level Physiological Consequences

In the myometrium, the EP3-mediated decrease in cAMP alters the activity of protein kinase A (PKA), leading to increased intracellular calcium mobilization and calcium-dependent myosin light chain phosphorylation. This ultimately results in myometrial contraction. Concurrently, in the gastrointestinal system, activation of these receptors leads to increased bicarbonate secretion and enhanced mucus production in the gastric pits, modulating the local environment.

Dosage and Administration Information

How to Use Misotac

The usage of Misotac (misoprostol) depends on the specific application. The administration route, dose, and frequency align with established protocols. The medication is supplied in 100 microgram (mug) and 200 mug tablet strengths.


Administration Routes and Dosing

Primary Use Context Approved Route(s) Standard Adult Regimen Frequency and Duration
NSAID-Induced Ulcer Prophylaxis Oral 200 mug Four times daily (QID). Continued for the duration of NSAID therapy.
Medical Termination of Pregnancy Buccal (most common route) 800 mug (single dose) Administered 24 to 48 hours after mifepristone.

Administration Conditions and Procedural Steps

For ulcer prophylaxis, the oral tablets are administered with food to minimize common gastrointestinal discomfort. The final daily dose is typically taken at bedtime. If a dose is missed, the standard instruction is to skip the missed dose if the next one is due soon and to not double the dose.

In the buccal regimen, the single 800 mug dose consists of placing four 200 mug tablets two in each cheek pouch (between the cheek and gum). The tablets are held in place for 30 minutes to allow for dissolution. Any remaining tablet fragments are then swallowed with liquid. These procedural instructions should be followed exactly as described.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Misotac

Evidence for use in Medically Inducing Labor

Research was studied for its role in medically inducing labor in pregnant individuals who are at term. The majority of the studies was evaluated in clinical trial settings, including many that compared Misotac to a placebo (an inactive treatment) or to other established induction methods. These studies monitored outcomes related to systemic or functional imbalance, specifically looking at how the cervix changes and the onset of labor contractions. The findings describe patterns observed in the studies related to the physiological changes during the observed time interval.

However, the evidence quality varies across studies, and research is ongoing to explore patterns related to its use. Comparative evidence is lacking in some specific settings, and subgroup findings are uncertain for certain factors that may influence the timing of labor.


Evidence for use in Managing Postpartum Hemorrhage

Misotac was studied for research exploring outcomes related to postpartum hemorrhage (excessive bleeding after childbirth). This research examined its role, primarily in emergency or resource-limited settings. Research explored whether there were data show patterns related to outcomes monitoring physiological strain or stress following delivery.

Research explored studies that examined temporary physiological imbalance related to this acute condition. These findings contribute to the broader evidence landscape of perceived discomfort during the observed time interval. Despite the existing data, the long-term effects are not fully established after using Misotac, and data are still emerging regarding its comparative use. Follow-up durations were limited in many studies, meaning information on extended outcomes remains limited.


Groups Where Evidence is Less Clear or Different: Evidence in Special Populations

Research monitored populations with specific pre-existing or comorbid conditions where Misotac was studied for its use. This research describes some of the patterns observed in individuals who may have conditions marked by functional limitations or specific health risks. It is important to remember that results apply only to the populations studied, and the evidence quality varies across studies when looking at these distinct subgroups.

Frequently Asked Questions (FAQ)

Common questions about Misotac (FAQ)


Q: Why is Misotac used for conditions other than its original purpose?

Misoprostol, the active ingredient in Misotac, was initially approved to help prevent stomach ulcers caused by certain pain medicines. However, official information recognizes its dual-action property as a prostaglandin analog. This means it can also mimic natural compounds that stimulate the uterus, which led to its regulated use in obstetric protocols, such as for medical termination of pregnancy.


Q: How long do the effects of Misotac typically last?

Studies examining the drug’s behavior in the body indicate that the active metabolite, misoprostol acid, has a short elimination half-life, meaning it loses half of its activity in approximately 20 to 40 minutes. The substance is generally understood to be cleared from the body within a few hours, though individual clearance times may vary.


Q: What is the general timeframe for Misotac to start having an effect?

The time it takes for Misotac to begin working is influenced by the way it is administered and its intended purpose. In the regulated regimen for medical termination of pregnancy, the onset of effect, such as the beginning of uterine contractions, is typically observed between 2 and 24 hours after administering misoprostol.


Q: Is it true that Misotac can be used to treat stomach ulcers?

Official prescribing information states that Misotac is indicated for the prevention of stomach ulcers in individuals who are taking nonsteroidal anti-inflammatory drugs (NSAIDs) and are considered high-risk. It functions as a protective agent for the gastric lining, which is the layer of cells inside the stomach.


Q: Can men use Misotac for any specific conditions?

Yes, regulatory documents confirm that men are eligible to use Misotac for its function as a gastric mucosal protective agent. This means it can be prescribed to men for the prevention of stomach ulcers that may be caused by taking certain NSAID pain relievers.


Q: Can Misotac affect my regular menstrual cycle?

Official safety data lists certain effects related to the female reproductive system, such as abnormal uterine contractions and painful menstruation, as rare adverse reactions. Official sources primarily document immediate adverse effects and do not address the long-term impact on the general regularity or timing of a person’s menstrual cycle.


Q: Are there any common food or drink items that should be avoided with Misotac?

For its use in ulcer prevention, the official labeling instructs that the tablets be administered with food. Official warnings and labels may address co-administration with other substances, but specific warnings about common food or drink items are not typically included. Warnings about alcohol, if present, are usually tied to its effect on judgment in conjunction with the drug.


Q: Is it common for people to experience chills or fever after using Misotac?

Yes, official safety documents indicate that temporary fever and rigors (involuntary shivering or chills) are known effects. These reactions are typically categorized as 'Uncommon,' meaning they are reported to occur in less than one in every 100 people who use the medication.


Q: What does the research say about Misotac's use in managing postpartum bleeding?

Misoprostol is included on the World Health Organization (WHO) Model List of Essential Medicines for the prevention and treatment of excessive bleeding after childbirth, known as postpartum hemorrhage. This inclusion signifies that the WHO recognizes evidence of its effectiveness and safety for this health need.


Q: Are there any official documents that specifically address the safety of Misotac for breastfeeding individuals?

Yes, authoritative resources like the NIH's LactMed database state that the levels of the active substance transferred into breast milk are considered very low and are not expected to cause adverse effects in a breastfed infant. However, manufacturers may include a caution or recommendation against use, which is a statement of conservative practice based on the lack of comprehensive clinical studies.


Q: Why is Misotac sometimes referred to by different names?

Misotac is a specific brand name given to the product by a manufacturer. The medication is also commonly referred to by its generic and active ingredient name, misoprostol. Different companies market the same active ingredient under various brand names globally.


Q: Does Misotac cause drowsiness or affect the ability to drive?

Official lists of potential side effects include dizziness as a common reaction and drowsiness as a less frequently reported one. Individuals should be aware that the presence of such effects has the potential to affect activities requiring mental alertness.


Q: How quickly does Misotac leave the body after it is used?

The active metabolite of misoprostol, misoprostol acid, has a very short elimination half-life of 20–40 minutes. The compound is rapidly cleared, and a typical dose is often no longer reliably detectable in the blood after six hours.


Q: Are there any age restrictions mentioned in official documents for Misotac use?

For pediatric patients (under 18), official regulatory documents often state that the medication’s safety and effectiveness for ulcer prevention have not been established. Official labeling for older adults notes that caution may be necessary because they may be more sensitive to the medication's effects, potentially requiring dose consideration.


Q: Does having an IUD affect eligibility for Misotac use?

Official prescribing information generally addresses contraception, but not all specific devices are detailed. However, in certain clinical protocols for obstetric use, the presence of an Intrauterine Device (IUD) or certain uterine anomalies may be listed as an exclusion criterion.


Q: Is the onset time of Misotac affected by how it is administered?

Studies examining the drug’s absorption show that the route of administration does affect how quickly the active substance is concentrated in the blood. For example, some routes, like sublingual (under the tongue), may achieve peak concentrations faster than the oral route.


Q: What is the typical difference between how Misotac and Mifepristone are used?

These are two separate medications used in sequence for a regulated regimen. Mifepristone is typically administered first to block a specific hormone (progesterone). Misoprostol is then administered 24 to 48 hours later to induce contractions and facilitate the emptying of the uterus. They perform different, sequential actions.


Q: Why is detailed eligibility information so critical for Misotac?

Eligibility information is critical because Misotac carries a major regulatory warning (Boxed Warning) from authorities like the FDA. This warning highlights the significant risk of serious adverse outcomes, including fetal death and uterine rupture, in certain populations, necessitating strict patient selection.


Q: Is Misotac known to have any effect on future fertility?

Available research evidence indicates that use of misoprostol does not appear to impair future fertility.


Q: Does Misotac have to be taken at a specific time of day?

For its use in preventing stomach ulcers, official instructions often specify that the final daily dose should be administered at bedtime. For its use in regulated obstetric regimens, the timing is specifically set to be 24 to 48 hours after the first medication (mifepristone).


Q: Are there any specific organs or body systems that Misotac heavily impacts?

Yes, Misoprostol is officially designated as having two key functional roles, which define its primary impact areas. It acts as a protective agent on the lining of the gastrointestinal system and as a contracting agent on the smooth muscle of the uterus.


Q: Is Misotac effective for its registered purpose in all individuals?

Clinical studies and regulatory data describe the effectiveness rates for its registered purposes. Effectiveness is determined by clinical data, and individual outcomes can vary based on personal health factors.


Q: Is the use of Misotac supported by any major international health organizations?

Yes, Misoprostol is recognized and supported by major bodies such as the World Health Organization (WHO). The WHO includes it on its Model List of Essential Medicines, a list reserved for drugs considered highly effective and safe for priority health needs.


Q: What kind of research has been done on using Misotac in different countries?

Misoprostol has been extensively studied globally. Research has been conducted through multinational clinical trials and observational studies, particularly to develop and refine regulated protocols for its obstetric uses in various countries and resource settings.

How should Misotac be stored and disposed of?

How to Store and Dispose of Misotac?

The storage of Misotac (misoprostol) tablets must strictly follow official regulatory requirements to maintain drug stability.

Official Storage Conditions

Misotac must be stored at controlled room temperature, specifically at or below 25°C (77°F), and should not be stored above 30°C or allowed to freeze. The medication must be kept in the original container, which should be tightly closed, to protect it from the primary drivers of degradation: moisture and direct light.

Handling and Disposal

It is mandatory to keep this medication out of the reach of children. When disposing of unused or expired Misotac, do not flush the tablets down the toilet or put them in household waste. Instead, follow instructions from a healthcare professional or use an official medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Misotac found in:

A-Z Index: